Investment, Funding & Disinvestments

The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.

The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.

LEO Pharma will gain access to Replay’s proprietary high-payload herpes simplex virus (HSV) delivery platform, an innovative technology designed to deliver large therapeutic genes directly into skin cells.

Under the terms of the agreement, Chiesi will purchase KalVista for US$27 per share, representing a 36% premium over the company’s closing stock price on April 28.

The collaboration focuses on multiple research programmes designed to develop and commercialise site-specific recombinases for diseases characterised by severe unmet medical needs.

The liver centre combines several specialties, including hepatobiliary surgery, hepatology, gastroenterology, oncology, and interventional radiology.

The company expects the facility to increase production capacity and improve supply chain responsiveness across the Middle East and Africa (MEA).

Globally, Heidi supports more than 2.5 million consultations each week as part of its broader mission to expand healthcare capacity.

The project received financial backing from First City Monument Bank (FCMB) and the Bank of Industry (BoI), reflecting a coordinated push to support local industry growth.